{"id":9477,"date":"2026-07-22T08:00:00","date_gmt":"2026-07-22T06:00:00","guid":{"rendered":"https:\/\/www.msd.ch\/fr\/?post_type=news_item&#038;p=9477"},"modified":"2026-07-21T17:36:58","modified_gmt":"2026-07-21T15:36:58","slug":"approuve-keytruda-cancer-ovaire","status":"publish","type":"news_item","link":"https:\/\/www.msd.ch\/fr\/news\/approuve-keytruda-cancer-ovaire\/","title":{"rendered":"Swissmedic approuve KEYTRUDA\u00ae (Pembrolizumab) en association au paclitaxel, avec ou sans b\u00e9vacizumab, est indiqu\u00e9 dans le traitement de patientes adultes atteintes d\u2019un carcinome \u00e9pith\u00e9lial de l\u2019ovaire, des trompes de Fallope ou p\u00e9riton\u00e9al primitif r\u00e9sistant aux sels de platine dont les tumeurs expriment PD-L1 (CPS\u00a0\u2265 1) et ont re\u00e7u un ou deux traitements syst\u00e9miques ant\u00e9rieurs."},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[30],"class_list":["post-9477","news_item","type-news_item","status-publish","post-password-required","hentry","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KEYTRUDA\u00ae approuv\u00e9 dans le cancer de l&#039;ovaire r\u00e9sistant au platine<\/title>\n<meta name=\"description\" content=\"Autorisation de KEYTRUDA\u00ae en association avec le paclitaxel \u00b1 b\u00e9vacizumab pour le traitement du cancer de l&#039;ovaire r\u00e9sistant au platine avec PD-L1 (CPS \u22651).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/fr\/news\/approuve-keytruda-cancer-ovaire\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KEYTRUDA\u00ae approuv\u00e9 dans le cancer de l&#039;ovaire r\u00e9sistant au platine\" \/>\n<meta property=\"og:description\" content=\"Autorisation de KEYTRUDA\u00ae en association avec le paclitaxel \u00b1 b\u00e9vacizumab pour le traitement du cancer de l&#039;ovaire r\u00e9sistant au platine avec PD-L1 (CPS \u22651).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/fr\/news\/approuve-keytruda-cancer-ovaire\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/news\\\/approuve-keytruda-cancer-ovaire\\\/\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/news\\\/approuve-keytruda-cancer-ovaire\\\/\",\"name\":\"KEYTRUDA\u00ae approuv\u00e9 dans le cancer de l'ovaire r\u00e9sistant au platine\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/#website\"},\"datePublished\":\"2026-07-22T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/news\\\/approuve-keytruda-cancer-ovaire\\\/#breadcrumb\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/\",\"name\":\"msd.ch\",\"description\":\"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KEYTRUDA\u00ae approuv\u00e9 dans le cancer de l'ovaire r\u00e9sistant au platine","description":"Autorisation de KEYTRUDA\u00ae en association avec le paclitaxel \u00b1 b\u00e9vacizumab pour le traitement du cancer de l'ovaire r\u00e9sistant au platine avec PD-L1 (CPS \u22651).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/fr\/news\/approuve-keytruda-cancer-ovaire\/","og_locale":"en_US","og_type":"article","og_title":"KEYTRUDA\u00ae approuv\u00e9 dans le cancer de l'ovaire r\u00e9sistant au platine","og_description":"Autorisation de KEYTRUDA\u00ae en association avec le paclitaxel \u00b1 b\u00e9vacizumab pour le traitement du cancer de l'ovaire r\u00e9sistant au platine avec PD-L1 (CPS \u22651).","og_url":"https:\/\/www.msd.ch\/fr\/news\/approuve-keytruda-cancer-ovaire\/","og_site_name":"msd.ch","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/fr\/news\/approuve-keytruda-cancer-ovaire\/","url":"https:\/\/www.msd.ch\/fr\/news\/approuve-keytruda-cancer-ovaire\/","name":"KEYTRUDA\u00ae approuv\u00e9 dans le cancer de l'ovaire r\u00e9sistant au platine","isPartOf":{"@id":"https:\/\/www.msd.ch\/fr\/#website"},"datePublished":"2026-07-22T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.msd.ch\/fr\/news\/approuve-keytruda-cancer-ovaire\/#breadcrumb"},"inLanguage":"en-US"},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/fr\/#website","url":"https:\/\/www.msd.ch\/fr\/","name":"msd.ch","description":"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/9477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":9,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/9477\/revisions"}],"predecessor-version":[{"id":9490,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/9477\/revisions\/9490"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/media?parent=9477"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/tags?post=9477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}